



Improving life from the inside out

Nuvios Inc.
300 Technology Square
5th Floor
Cambridge, MA 02139
(617) 551-4700
(617) 551-4701 Fax
www.nuvios.com

FOR IMMEDIATE RELEASE

CONTACT:

Bart Henderson
Chief Business Officer
Nuvios, Inc.
(617) 551-4702
bhenderson@nuvios.com

NUVIOS NAMES DR. CHRISTOPHER GLASS TO SCIENTIFIC ADVISORY BOARD

— Leader in nuclear receptor biology—

CAMBRIDGE, Mass., November 12, 2004— Nuvios, Inc. today announced the appointment of Christopher K. Glass, MD, PhD, of the Department of Cellular and Molecular Medicine at the University of California, San Diego, to the company's Scientific Advisory Board.

“Dr. Glass is a pioneer in the study of nuclear receptors, which are key targets for a number of major drugs. Combining his expertise with our focus on nongenotropic signaling has great potential for discovering new drugs for osteoporosis and other major indications in women's health and metabolic diseases,” said C. Richard Lyttle, PhD, President and Chief Executive Officer of Nuvios. “He joins a truly distinguished board of leading scientists in the fields of bone biology and chemistry, as well as metabolic disorders. We look forward to his expertise and guidance as Nuvios advances its lead ANGELS™ technology and other programs based on nongenotropic signaling.”

ANGELS™ have the potential to be a new class of osteoporosis drugs that restore lost bone. Nuvios is applying recent discoveries around the biology of nongenotropic cellular pathways to develop ANGELS™ as anabolic agents that build and strengthen bone without increasing the risks of cancer and cardiovascular disease. Nuvios will also apply its discovery approach in nongenotropic signaling to other conditions affected by nuclear receptors such as diabetes, asthma, psoriasis, and menopause.

“I am very excited to be working with the Nuvios team,” said Dr. Glass. “The company's paradigm of dissociating genotropic from nongenotropic signaling is very promising for developing new therapies for osteoporosis and other major diseases. A number of important drugs target this class of receptors, and there will likely be significant new discoveries in this field using the Nuvios approach.”

(MORE...)

Dr. Glass is a founding member of the Department of Cellular and Molecular Medicine at the University of California, San Diego, where he is currently Professor of Cellular and Molecular Medicine and Professor of Medicine. Prior to his appointment as Professor, Dr. Glass was a postdoctoral fellow in Endocrinology and Metabolism at UCSD, following internships and residency training at Harvard Medical School's Brigham and Women's Hospital. He received a BS in Biophysics from the University of California, Berkeley, and MD and PhD degrees from UCSD.

ABOUT NUVIOS

Nuvios is a leader in the discovery and development of a new generation of drug therapies for treating and preventing osteoporosis and metabolic bone diseases. The company's primary focus is on discoveries related to the growth of osteoblasts and osteoclasts, which enable the formation of bone with high specificity. Nuvios is a privately held biotechnology company located in Cambridge, Massachusetts. The company raised \$24 million in its first institutional financing in 2003. Investors include HealthCare Ventures, MPM Capital, and Oxford Bioscience Partners. www.nuvios.com

###